Compare NBTB & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBTB | ZLAB |
|---|---|---|
| Founded | 1856 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.6B |
| IPO Year | 1995 | 2017 |
| Metric | NBTB | ZLAB |
|---|---|---|
| Price | $50.61 | $21.06 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 12 |
| Target Price | ★ $57.17 | $34.21 |
| AVG Volume (30 Days) | 237.5K | ★ 1.1M |
| Earning Date | 10-27-2026 | 11-05-2026 |
| Dividend Yield | ★ 3.15% | N/A |
| EPS Growth | 12.12 | ★ 38.46 |
| EPS | ★ 3.10 | N/A |
| Revenue | $182,952,000.00 | ★ $460,156,000.00 |
| Revenue This Year | $9.31 | N/A |
| Revenue Next Year | $5.48 | $22.47 |
| P/E Ratio | $16.37 | ★ N/A |
| Revenue Growth | 10.40 | ★ 15.33 |
| 52 Week Low | $40.13 | $15.96 |
| 52 Week High | $55.35 | $29.02 |
| Indicator | NBTB | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 39.79 | 36.38 |
| Support Level | $49.89 | $17.35 |
| Resistance Level | $51.09 | $26.64 |
| Average True Range (ATR) | 1.04 | 1.37 |
| MACD | -0.33 | -0.33 |
| Stochastic Oscillator | 9.16 | 10.89 |
NBT Bancorp Inc is a financial holding company that operates through its subsidiaries. The company's principal sources of revenue include management fees and dividends it receives through its subsidiaries. Its business, predominantly conducted through NBT Bank, consists of providing commercial banking, retail banking, and wealth management services to customers in its market area, which includes upstate New York, northeastern Pennsylvania, southern New Hampshire, western Massachusetts, Vermont, southern Maine, and central and northwestern Connecticut. The company's reportable segments are Banking and Retirement Plan Administration. A majority of its revenue is generated from the Banking segment.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.